| Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease O Preische, SA Schultz, A Apel, J Kuhle, SA Kaeser, C Barro, S Gräber, ... Nature medicine 25 (2), 277-283, 2019 | 729 | 2019 |
| Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study BA Gordon, TM Blazey, Y Su, A Hari-Raj, A Dincer, S Flores, ... The Lancet Neurology 17 (3), 241-250, 2018 | 495 | 2018 |
| The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model RJ Bateman, TL Benzinger, S Berry, DB Clifford, C Duggan, AM Fagan, ... Alzheimer's & Dementia 13 (1), 8-19, 2017 | 265 | 2017 |
| Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease E McDade, G Wang, BA Gordon, J Hassenstab, TLS Benzinger, V Buckles, ... Neurology 91 (14), e1295-e1306, 2018 | 249 | 2018 |
| A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease S Salloway, M Farlow, E McDade, DB Clifford, G Wang, JJ Llibre-Guerra, ... Nature medicine 27 (7), 1187-1196, 2021 | 221 | 2021 |
| Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis G Klein, P Delmar, N Voyle, S Rehal, C Hofmann, D Abi-Saab, ... Alzheimer's research & therapy 11, 1-12, 2019 | 182 | 2019 |
| Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers BA Gordon, TM Blazey, J Christensen, A Dincer, S Flores, S Keefe, ... Brain 142 (4), 1063-1076, 2019 | 142 | 2019 |
| Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies Y Su, S Flores, G Wang, RC Hornbeck, B Speidel, N Joseph‐Mathurin, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (1 …, 2019 | 100 | 2019 |
| Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease SE Schindler, Y Li, KW Todd, EM Herries, RL Henson, JD Gray, G Wang, ... Alzheimer's & Dementia 15 (5), 655-665, 2019 | 87 | 2019 |
| Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis G Wang, RA Marrie, RJ Fox, T Tyry, SS Cofield, GR Cutter, A Salter Multiple sclerosis and related disorders 20, 16-21, 2018 | 43 | 2018 |
| Differences in Alzheimer disease clinical trial outcomes based on age of the participants LS Schneider, RE Kennedy, G Wang, GR Cutter Neurology 84 (11), 1121-1127, 2015 | 42 | 2015 |
| Health insurance affects the use of disease-modifying therapy in multiple sclerosis G Wang, RA Marrie, AR Salter, R Fox, SS Cofield, T Tyry, GR Cutter Neurology 87 (4), 365-374, 2016 | 40 | 2016 |
| DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network (2017) The DIAN-TU next generation Alzheimer’s prevention trial: adaptive design and disease … RJ Bateman, TL Benzinger, S Berry, DB Clifford, C Duggan, AM Fagan, ... Alzheimers Dement 13, 8-19, 0 | 38 | |
| Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease O Preische, SA Schultz, A Apel, J Kuhle, SA Kaeser, C Barro, S Gräber, ... Nat. Med. 25 (2), 277-283, 2019 | 37 | 2019 |
| Predicting symptom onset in sporadic Alzheimer disease with amyloid PET SE Schindler, Y Li, VD Buckles, BA Gordon, TLS Benzinger, G Wang, ... Neurology 97 (18), e1823-e1834, 2021 | 34 | 2021 |
| A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease G Wang, S Berry, C Xiong, J Hassenstab, M Quintana, EM McDade, ... Statistics in medicine 37 (21), 3047-3055, 2018 | 34 | 2018 |
| Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? RE Kennedy, GR Cutter, G Wang, LS Schneider Alzheimer's & Dementia: Translational Research & Clinical Interventions 1 (1 …, 2015 | 32 | 2015 |
| Association of longitudinal changes in cerebrospinal fluid total tau and phosphorylated tau 181 and brain atrophy with disease progression in patients with Alzheimer disease JJ Llibre-Guerra, Y Li, SE Schindler, BA Gordon, AM Fagan, JC Morris, ... JAMA network open 2 (12), e1917126-e1917126, 2019 | 29 | 2019 |
| Challenging assumptions about African American participation in Alzheimer disease trials RE Kennedy, GR Cutter, G Wang, LS Schneider The American Journal of Geriatric Psychiatry 25 (10), 1150-1159, 2017 | 28 | 2017 |
| Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS A Salter, T Tyry, G Wang, RJ Fox, G Cutter, RA Marrie Neurology: Clinical Practice 6 (5), 397-408, 2016 | 24 | 2016 |
Randall BatemanWashington University in St. LouisVerified email at wustl.edu
